The primary endpoint was reduction in spasticity, as determined by the Ashworth score, over 12 h following dosing. Torreya is not involved with the marketing or sale of these products, nor in the management of any clinical trials. In December 2008, data from the 7-week, open-label, extension part of the study were reported. As previously announced on July 31, 2008, Arthur A. Torreya welcomes inquiries from qualified industry professionals concerning Torreya's services and will respond to these inquiries as soon as possible. However, by July 2011, the trial had been put on hold.
The drug is no longer listed on the company's website. To listen to the live presentation, please go to the web site 15 minutes prior to its start to register, download, and install the necessary audio software. The conference will be held at the Southampton Inn, Long Island, New York. It is reported in about two to three million patients in the U. However, these medications will be allowed during open label study. The subject must agree to take every precaution to ensure that pregnancy will not occur during the study.
If female and of childbearing potential, continuing to practice and willing to continue throughout the study with appropriate contraceptives defined as oral, injected, or implanted contraceptives, or barrier contraception. No 511 Last Updated On Jul 18, 2015 Spasticity is characterized by muscle stiffness and involuntary muscle spasms. In addition, the neurology market is readily addressable by a small and focused sales force, given the concentration of physicians writing prescriptions. Kim Sutton Golodetz 212-838-3777 or Bruce Voss 310-691-7100. Female subjects of childbearing potential must have a negative urine pregnancy test immediately prior to study entry. .
Accordingly, Torreya is unable to respond to requests for consumer information concerning any products in the deals. The study was expected to complete in February 2008. . . . .
. . . . . .
. . . . . .
. . . . .
. . . . .
. . . . . . .